Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$79.0 M
Burn Rate (Qtr)
$8.2 M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q1 '22
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
AVEO
Company Profile
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients’ lives with clear unmet medical needs. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company’s website at www.aveooncology.com.
Recent Posts
See what the community is saying - click to see full post.